One of the most persistent fears around testosterone replacement therapy (TRT) is the concern that it might harm the heart. This fear was amplified by a flawed 2010 study and several years of negative media coverage. But the medical literature in 2026 paints a very different picture — one that suggests low testosterone itself is a significant cardiovascular risk factor, and that TRT, when properly administered and monitored, may actually protect heart health.
The TRAVERSE Trial — Definitive Evidence
The most rigorous long-term trial on TRT and cardiovascular safety was the TRAVERSE trial, published in the New England Journal of Medicine in 2023. This randomized controlled trial followed over 5,200 men aged 45–80 with low testosterone and pre-existing or elevated risk of cardiovascular disease for an average of 33 months. The result: testosterone therapy did NOT increase the risk of major adverse cardiac events (heart attack, stroke, or cardiovascular death) compared to placebo.
The trial did note a small but statistically significant increase in pulmonary embolism (blood clot in the lungs) and atrial fibrillation — effects associated with elevated hematocrit (red blood cell count), which is a known and monitorable effect of TRT. This is why proper monitoring — including regular CBC blood panels — is non-negotiable in any responsible TRT program.
The Evidence That Low Testosterone Is the Real Cardiovascular Risk
Multiple large studies have found that men with low testosterone have significantly higher rates of cardiovascular disease, metabolic syndrome, and all-cause mortality. Testosterone supports heart function in several ways:
- Promotes vasodilation (widening of blood vessels), reducing blood pressure
- Reduces visceral fat accumulation, a primary driver of cardiovascular inflammation
- Improves insulin sensitivity and reduces the risk of type 2 diabetes
- Supports lean muscle mass, which correlates with better metabolic health
- Has direct anti-inflammatory effects on arterial walls
The Importance of Monitoring
The key to cardiovascular safety with TRT is proper monitoring and management. At MultiGen Wellness, every patient on TRT receives:
- Baseline and regular CBC to monitor hematocrit levels (we target <54%)
- Regular testosterone panels to keep levels in the therapeutic range
- Estradiol monitoring to manage aromatization
- Blood pressure tracking
- Symptom assessment at every follow-up
Get the facts about TRT safety from our expert physicians. Call (800) 259-0015 or book your free consultation today.